Clinical Trial

Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence (CHOICE-2)

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Hyperthermic intrathoracic chemotherapy (HITOC) offers a strategy to eliminate microscopic residual disease after surgical resection. Especially it is investigated to improve long-term survival in thymic epithelial tumors with pleural dissemination or recurrence. A prospective, multicenter, randomized phase III clinical trial (CHOICE-2) is conducted to compare the efficacy and safety of surgery combined with HITOC versus surgery alone. The HITOC regimen involves intrathoracic perfusion with doxorubicin on postoperative day 1 and cisplatin on postoperative day 2.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-01.
Trial Details
NCT Number NCT07383142
Lead Sponsor Shanghai Zhongshan Hospital
Collaborators: Sir Run Run Shaw Hospital, West China Hospital, Liaoning Cancer Hospital & Institute, Fujian Medical University Union Hospital, Qilu Hospital of Shandong University, Jiangxi Provincial People's Hopital, Zhongshan Hospital (Xiamen), Fudan University, Tang-Du Hospital, Xuhui Central Hospital, Shanghai
Conditions Thymic Epithelial Tumor
Enrollment 202 participants
Start Date 2026-02-01
Primary Completion 2029-02-01 (estimated)
Study Completion 2032-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-06